CD79A and cancer: Although IgA has been proven to be particularly effective in activating neutrophils, the numerous regulators overexpressed on tumor cells indicate that antibody-driven cytotoxicity alone is insufficient to battle cancer, and that antibody therapy should be combined with checkpoint inhibition to be effective (9).